On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: A secondary analysis of the His-SYNC Pilot Trial

医学 心脏再同步化治疗 心脏病学 内科学 射血分数 心脏起搏 心力衰竭 捆绑 复合材料 材料科学
作者
Gaurav A. Upadhyay,Pugazhendhi Vijayaraman,Hemal M. Nayak,Nishant Verma,Gopi Dandamudi,Parikshit S. Sharma,Moeen Saleem,John Mandrola,Davide Genovese,Jess W. Oren,Faiz A. Subzposh,Zaid Aziz,Andrew D. Beaser,Dalise Y. Shatz,Stephanie A. Besser,Roberto M. Lang,Richard G. Trohman,Bradley P. Knight,Roderick Tung
出处
期刊:Heart Rhythm [Elsevier BV]
卷期号:16 (12): 1797-1807 被引量:196
标识
DOI:10.1016/j.hrthm.2019.05.009
摘要

BackgroundThe His-SYNC pilot trial was the first randomized comparison between His bundle pacing in lieu of a left ventricular lead for cardiac resynchronization therapy (His-CRT) and biventricular pacing (BiV-CRT), but was limited by high rates of crossover.ObjectiveTo evaluate the results of the His-SYNC pilot trial utilizing treatment-received (TR) and per-protocol (PP) analyses.MethodsThe His-SYNC pilot was a multicenter, prospective, single-blinded, randomized, controlled trial comparing His-CRT vs BiV-CRT in patients meeting standard indications for CRT (eg, NYHA II–IV patients with QRS >120 ms). Crossovers were required based on prespecified criteria. The primary endpoints analyzed included improvement in QRS duration, left ventricular ejection fraction (LVEF), and freedom from cardiovascular (CV) hospitalization and mortality.ResultsAmong 41 patients enrolled (aged 64 ± 13 years, 38% female, LVEF 28%, QRS 168 ± 18 ms), 21 were randomized to His-CRT and 20 to BiV-CRT. Crossover occurred in 48% of His-CRT and 26% of BiV-CRT. The most common reason for crossover from His-CRT was inability to correct QRS owing to nonspecific intraventricular conduction delay (n = 5). Patients treated with His-CRT demonstrated greater QRS narrowing compared to BiV (125 ± 22 ms vs 164 ± 25 ms [TR], P < .001;124 ± 19 ms vs 162 ± 24 ms [PP], P < .001). A trend toward higher echocardiographic response was also observed (80 vs 57% [TR], P = .14; 91% vs 54% [PP], P = .078). No significant differences in CV hospitalization or mortality were observed.ConclusionsPatients receiving His-CRT on-treatment demonstrated superior electrical resynchronization and a trend toward higher echocardiographic response than BiV-CRT. Larger prospective studies may be justifiable with refinements in patient selection and implantation techniques to minimize crossovers. The His-SYNC pilot trial was the first randomized comparison between His bundle pacing in lieu of a left ventricular lead for cardiac resynchronization therapy (His-CRT) and biventricular pacing (BiV-CRT), but was limited by high rates of crossover. To evaluate the results of the His-SYNC pilot trial utilizing treatment-received (TR) and per-protocol (PP) analyses. The His-SYNC pilot was a multicenter, prospective, single-blinded, randomized, controlled trial comparing His-CRT vs BiV-CRT in patients meeting standard indications for CRT (eg, NYHA II–IV patients with QRS >120 ms). Crossovers were required based on prespecified criteria. The primary endpoints analyzed included improvement in QRS duration, left ventricular ejection fraction (LVEF), and freedom from cardiovascular (CV) hospitalization and mortality. Among 41 patients enrolled (aged 64 ± 13 years, 38% female, LVEF 28%, QRS 168 ± 18 ms), 21 were randomized to His-CRT and 20 to BiV-CRT. Crossover occurred in 48% of His-CRT and 26% of BiV-CRT. The most common reason for crossover from His-CRT was inability to correct QRS owing to nonspecific intraventricular conduction delay (n = 5). Patients treated with His-CRT demonstrated greater QRS narrowing compared to BiV (125 ± 22 ms vs 164 ± 25 ms [TR], P < .001;124 ± 19 ms vs 162 ± 24 ms [PP], P < .001). A trend toward higher echocardiographic response was also observed (80 vs 57% [TR], P = .14; 91% vs 54% [PP], P = .078). No significant differences in CV hospitalization or mortality were observed. Patients receiving His-CRT on-treatment demonstrated superior electrical resynchronization and a trend toward higher echocardiographic response than BiV-CRT. Larger prospective studies may be justifiable with refinements in patient selection and implantation techniques to minimize crossovers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
义气的妙松完成签到,获得积分10
2秒前
洪婉馨发布了新的文献求助10
3秒前
姜鸽完成签到,获得积分10
3秒前
liuyuh发布了新的文献求助10
3秒前
蔺凌完成签到 ,获得积分10
4秒前
xiaozheng完成签到,获得积分10
4秒前
zz发布了新的文献求助10
5秒前
Littlerain~完成签到,获得积分10
6秒前
慕辰完成签到,获得积分10
8秒前
9秒前
eve完成签到,获得积分20
12秒前
斯文败类应助洪婉馨采纳,获得10
12秒前
14秒前
彭于晏应助zz采纳,获得10
15秒前
lzd完成签到,获得积分10
18秒前
SciGPT应助海德堡采纳,获得10
19秒前
20秒前
稳重飞飞完成签到,获得积分10
20秒前
热心的善愁完成签到,获得积分10
20秒前
Muniira完成签到,获得积分10
21秒前
leyellows完成签到 ,获得积分10
23秒前
量子星尘发布了新的文献求助10
25秒前
睿睿躺不平给睿睿躺不平的求助进行了留言
26秒前
果果完成签到,获得积分10
26秒前
30秒前
30秒前
余十一完成签到 ,获得积分10
31秒前
31秒前
32秒前
JamesPei应助奋斗采纳,获得10
32秒前
wanci应助yn采纳,获得10
33秒前
liuyuh发布了新的文献求助10
33秒前
无糖乐发布了新的文献求助10
33秒前
无私的芹发布了新的文献求助10
33秒前
无私的芹发布了新的文献求助10
34秒前
无私的芹发布了新的文献求助10
34秒前
34秒前
35秒前
哭泣剑封完成签到,获得积分10
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969628
求助须知:如何正确求助?哪些是违规求助? 3514448
关于积分的说明 11174217
捐赠科研通 3249822
什么是DOI,文献DOI怎么找? 1795000
邀请新用户注册赠送积分活动 875537
科研通“疑难数据库(出版商)”最低求助积分说明 804856